Hear me Roar

Houston-based B2B tech company is connecting the dots on IT services

Houston-based Liongard's Roar technology is helping its customers get all their IT services under one umbrella. Getty Images

Houston-based startup Liongard, an Information Technology automation and management company, was founded on the idea that managing data and technology for companies shouldn't be so difficult.

Before founding Liongard, CEO Joe Alapat and COO Vincent Tran owned and operated Empact IT, an IT company, for more 10 years. In the decade they owned the company, Alapat said they saw the industry completely change as protecting a business' information and data became more challenging.

"[IT is] not all on one place in a data center anymore: it's in the Cloud, it's on the network, it's in app services and in on-premise [offices]," Alapat says. "The security problem is huge and that's exploding because … we lack visibility into basic things when we're managing IT. We just want to be able to manage it and get back to sanity."

After the duo sold the IT company in 2012, Alapat and Tran used the funds from the sale to launch Liongard in 2015 with the focus of automating the management of the plethora of systems that can overwhelm Managed Service Providers, or IT Service Providers.

"Everyone thinks their IT department is high-tech," Alapat says. "Unfortunately, the department that's supposed to be so high-tech is actually pretty manual. And they won't let on that it's challenging, but it really is [and] there's a lot of manual work involved."

So, Alapat and Tran developed Roar: a software product that creates a single dashboard for all data systems including the Cloud and apps, server networks, and on-site systems to make accessing and protecting the data easier. Alapat said Roar is able to inspect multiple systems and bring back rich information without logging into each different system.

Liongard joined entrepreneurial accelerator Station Houston — an association that helps place young businesses in front of investors — in June 2016 and gained access to its network of mentors, advisers, and investors.

In spring 2018, Liongard completed its Seed Stage round of its capital campaign with $1.3 million in investments. With these initial funds, Liongard was able to put Roar on the market in April 2018 and expand its client base — growing from two clients to now close to 200 customers in less than a year.

This year, the company will launch the second leg of its capital campaign with the goal of raising between $3 million to $4 million to help expand the company further.

Alapat said he thinks the company has been received well by Houston investors because Liongard offers a product that other IT management companies don't.

"No one has a unified way to look across the Cloud and network and apps and services and servers," Alapat

says. "There's plenty of different dashboards and solutions that looks at one or two of those things, but there's no single solution that consolidates all of that. That's what makes us different — that we unify all of that under one umbrella."

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News